1) Di Carlo V, Socci C, Principi generali sui trapianti d'organo, in: Dionigi R, Chirurgia, basi teoriche e chirurgia generale. Volume 1. Milano, Masson, 2006.

BIBLIOGRAFIA:

1) Di Carlo V, Socci C, Principi generali sui trapianti d'organo, in: Dionigi R, Chirurgia, basi teoriche e chirurgia generale. Volume 1. Milano, Masson, 2006.

2) Pirsch JD, Trattamento del paziente sottoposto a trapianto, in Simposi Clinici. Varese, Novartis, 1999.

Numero 17.

3) http://www.trapianti.ministerosalute.it

4) Schafer DF, Liver transplantation. Looking back, looking forward. In: Transplantation of the Liver, Philadelphia, Lippincott Williams & Wilkins, 2001.

5) Berardinelli L, Vegeto A, Trapianto di rene, in: Dionigi R, Chirurgia, chirurgia specialistica. Milano, Masson, 2006. Volume 2.

6) Maggi U, Fassati LR, Trapianto di fegato, in Dionigi R, Chirurgia, chirurgia specialistica. Milano, Masson, 2006. Volume 2.

7) Venettoni S, Ghiradini A, La figura del Coordinatore Locale al prelievo nel sistema italiano: ruolo e funzioni. Centro Nazionale Trapianti, ISS, Roma (TPM IV edizione)

8) Venettoni S, Ghiradini A, Il Sistema organizzativo dei trapianti in Italia: il livello nazionale. Centro Nazionale Trapianti, ISS, Roma (TPM IV edizione)

9) Di Ciaccio P, Ghirardini A, The Eurodonor project: an attempt of harmonization. Italian National Transplant Centre, Rome, Italy.

10) ITALIA. Legge 1 aprile 1999, n. 91. Disposizioni in materia di prelievi e trapianti di organi e di tessuti. G.U. 15 aprile 1999, n. 87.

11) ITALIA. Legge 26 giugno 1967, n. 458. Trapianto di rene tra persone viventi. G.U. 27 giugno 1967, n. 160.

12) ITALIA. Legge 16 dicembre 1999, n. 483. Norme per consentire il trapianto parziale di fegato. G.U.

20 dicembre 1999, n. 297.

13) ITALIA. Legge 29 dicembre 1993, n. 578. Norme per l’accertamento e la certificazione di morte.

G.U. 08 gennaio 1994, n. 5.

14) Walker AE, Cerebral Death, Second Edition, Urban and Schwarzenberg. 1981.

15) Sommerer C, Wiesel M, et al. The living kidney donor: giving life, avoiding harm, Nephrology Dialysis Transplant. 2003.18: 23-26.

16) Trotter JF, Adam R, et al. Documented deaths of hepatic lobe donors for living donor liver transplantation, Liver Transplantation. 2006. 12(10): 1485-1488.

17) ITALIA. Provvedimento Conferenza Stato-Regioni 31 gennaio 2002. Linee guida per il trapianto renale da donatore vivente e cadavere. G.U. 21 giugno 2002 n. 144.

18) Lake DF, Akporiaye ET, Immunofarmacologia, in: Katzung BG, Farmacologia generale e clinica.

Padova, Piccin Nuova Libraria. 2003.

19) Pelletier SJ, Crabtree TD, Gleason TG, et al. Characteristics of infectious complications associated with mortality after solid organ transplantation, Clinical Transplantation. 2000; 14: 401-8.

20) Rubin RH, Schaffner A, Speich R, Introduction to the immunocompromised host society consensus conference on epidemiology, prevention, diagnosis and management of infections in solid-organ transplant patients, Clinical Infectious Diseases. 2001; 33 (Suppl 1): S1-4.

21) Fisher SA, Infections complicating solid-organ transplantation, Surgical Clinics of North America, Elsevier Saunders. 2006; Volume 86, 1127-1145.

22) Fishman JA, Infection in Solid-Organ Transplant Recipients, New England Journal of Medicine.

2007; 357:2601-14.

23) American Journal of Transplantation. Copenaghen, Blackwell Munksgaard. 2004; Volume 4 (Suppl.

10): 5.

24) Sawyer RG, Crabtree TD, Gleason TG et al. Impact of solid organ transplantation and immunosuppression on fever, leukocytosis, and physiologic response during bacterial and fungal infections. Clinical Transplantation 1999. Munksgaard. 1999; 13: 260-265.

25) http://www.ail.it

26) Kowalski RJ, Post DR, Mannon RB et al. Assessing relative risks of infection and rejection: a meta- analysis using an immune function assay. Transplantation. 2006; 82: 663-668.

27) Lopez-Medrano F, Aguado JM, Lizasoain M, et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation. 2007; 84: 851-6.

28) Ho M, Dummer JS, Fattori di rischio e approcci alle infezioni nei trapiantati, in: Mandell GL, Douglas G Jr, Bennett JE, Principi e pratica delle malattie infettive, Padova, Piccin Nuova Libraria.

29) Fishman JA, Rubin RH, Infection in organ-transplant recipients. New England Journal of Medicine.

1998; 338: 1741-51.

30) Patel R, Paya CV, Infections in solid organ transplantation recipients. Clin Micro Rev 1997; 10: 86- 124.

31) Kusne S, Dummer JS, Ho M, et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine 1988; 67: 132-43.

32) Snydman DR. Epidemiology of infections after solid-organ transplantation. Clinical Infectious Diseases. 2001; 33 (Suppl 1): S5-8.

33) Becker BN, Becker YT, Heisey DM, et al. The impact of hypoalbuminemia in kidney-pancreas transplant recipients. Transplantation. 1999; 68: 72-5.

34) Guijarro C, Massy ZA, Wiederkehr MR, et al. Serum albumin and mortality after renal transplantation. Am J Kidney Dis. 1996; 27: 117-23.

35) Rubin RH. Infectious disease problems. In: Transplantation of the Liver. Philadelphia, Lippincott Williams & Wilkins, 2001.

36) Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrology Dialysis Transplantation. 2007; 22 (Suppl 1): i4-i10.

37) ITALIA, Centro Nazionale Trapianti. Linee guida per la valutazione di idoneità del donatore e

protocolli specifici. Revisione del 1 marzo 2005.

38) Venettoni S, Curtoni ES, Scalamogna M, et al. Strategies for evaluation of suitable donor: Italian experience. 2003. Centro Nazionale Trapianti.

39) Mueller NJ, Fishman JA. How should we evaluate organ donors with active or prior infections?

Journal of Epatology. 2006; 45: 483-513.

40) Lumbreras C, Sanz F, Gonzalez A, et al. Clinical significance of donor-unrecognized bacteriemia in the outcome of solid-organ transplant recipients. Clin Infect Dis. 2001; 33: 722-6.

41) Freeman RB, Giatras I, Falagas ME, et al. Outcome of transplantation of organs procured from bacteriemic donors. Transplantation. 1999; 68: 1107-11.

42) Schaffner A. Pretransplant evaluation for infections in donors and recipients of solid organs. Clinical Infectious Diseases. 2001; 33(Suppl 1): S9-S14.

43) Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation.

Clinical Infectious Diseases. 2001; 33(Suppl 1): S15-S21.

44) Molrine DC, Hibberd PL. Vaccines for transplant recipients. Infectious Disease Clinics of North America. 2001; 1: 273-305.

45) White DJC. Cyclosporin A. Amsterdam: Elsevier Biomedical Press, 1982.

46) Calne R. Recollections from the laboratory to the clinic, in: Terasaki PI, ed. History of

transplantation: thirty-five recollections. Los Angeles: UCLA Tissue Typing Laboratory, 1991; 4: 227- 243.

47) Imhof AE. Lost worlds: how our European ancestors coped with everyday life and why life is so hard today. Charlottesville: University Press of Virginia, 1996.

48) Brayman KL, Stephanian E, Matas J, et al. Analysis of infectious complications occurring after solid organ transplantation. Arch Surg. 1992; 127: 38-48.

49) Rubin RH. Infection in the organ transplant recipient, in: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host, 4

ed. New York: Plenum Publishing, 2000.

50) Rubin RH. The compromised host as sentinel chicken. N Engl J Med. 1987; 317: 1151-1153.

51) Pananicolau GA, Meyers BR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis. 1996; 23: 760-766.

52) Fortun J, Lopez-San Roman A, Velasco JJ, et al. Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Eur J Clin Microbiol Infect Dis. 1997; 16: 314-318.

53) Orloff SL, Busch AM, Olyaei AJ, et al. Vancomycin-resistant enterococci in liver tranplant patients.

Am J Surg. 1999; 177: 418-422.

54) Hopkins C, Weber DJ, Rubin RH. Invasive aspergillus infection: possible non-ward common source within the hospital environment. J Hosp Infect.1989; 12: 19-25.

55) Lebeau G, Yanaka K, Marsch JW, et al. Analysis of surgical complications after 397 hepatic tranplantations. Surg Gynecol Obstet. 1990; 170: 317-322.

56) George DL, Arnow PM, Fox AS, et al. Bacterial infection as a complication of liver transplantation:

epidemiology and risk factors. Rev Infect Dis. 1991; 13: 387-396.

57) Barkholt L, Ericzon BG, Tollemar J, et al. Infections in human liver recipients: different patterns early and later after transplantation. Transpl Int. 1993; 6: 77-84.

58) Garcia S, Rogue J, Ruza F, et al. Infection and associated risk factors in the immediate postoperative period of pediatric liver transplantation : a study of 176 transplants. Clin Transplant. 1998; 12: 190-197.

59) Arnow PM, Zachary KC, Thistlewaite JR, et al. Pathogenesis of early operative site infections after orthotopic liver transplantation. Transplantation.1998; 65: 1500-1503.

60) Gayowski T, Marino IR, Singh N, et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation. 1998; 65: 499-504.

61) Singh N. State of the science. Infection in solid-organ transplant recipients. Am J Infect Control.

1997; 25: 409-417.

62) Dunn DL, Acton RD. Solid-organ transplantation, in: Armstrong D, Cohen J. Infectious Diseases.

Volume One. MOSBY. Londra, 1999.

63) Hibberd PL, Rubin RH. Approach to immunization in the immunosuppressed host. Infect Dis Clin North Am. 1990; 4: 123-142.

64) Girndt M, Pietsch M, Kohler H. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis. 1995; 26: 454-460.

65) Huzly D, Neifer S, Reinke P, et al. Routine immunization in adult renal transplant recipients.

Transplantation. 1997; 63: 839-845.

66) Sever MS, Yildiz A, Eraksoy H, et al. Immune response to Haemophilus influenzae type B vaccination in renal transplant recipients with well-functioning allografts. Nephron. 1999; 81: 55-59.

67) Linnemann CC Jr, First MR, Schiffman G. Revaccination of renal transplant and haemodialysis recipients with pneumococcal vaccine. Arch Intern Med. 1986; 146: 1554-1556.

68) Centers for Disease Control and Prevention. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 1997; 46: 1-24.

69) Apalsch AM, Green M, Ledesma-Medina J, et al. Parainfluenza and influenza virus infections in pediatric organ transplant recipients. Clin Infect Dis. 1995; 20: 394-399.

70) Aschan J, Ringden O, Ljungman P, et al. Influenza B in transplant patients. Scand J Infect Dis. 1989;

21: 349-350.

71) Burbach G, Bienzle U, Stark K, et al. Influenza vaccination in liver transplant recipients.

Transplantation. 1999; 67: 753-755.

72) Sanchez-Fructuoso AI, Prats D, Naranjo P, et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols:

mycophenolate versus azathioprine. Transplantation. 2000; 69: 436-439.

73) Carey W, Pimentel R, Westveer MK, et al. Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial. Am J Gastroenterol. 1990; 85: 1590-1592.

74) Grob PJ, Binswanger U, Zaruba K, et al. Immunogenicity of a hepatitis B subunit vaccine in haemodialysis and in renal transplant recipients. Antiviral Res. 1983; 3: 43-52.

75) Jacobson IM, Jaffers G, Dienstag JL, et al. Immunogenicity of hepatitis B vaccine in renal transplant

recipients. Transplantation. 1985; 39: 393-395.

76) Loinaz C, de Juanez JR, Gonzalez EM, et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology. 1997; 44: 235-238.

77) Sokal EM, Ulla L, Otte JB. Hepatitis B vaccine response before and after transplantation in 55 extrahepatic biliary atresia children. Dig Dis Sci. 1992; 37: 1250-1252.

78) Van Thiel DH, el-Ashmawy L, Love K, et al. Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci. 1992; 37-1245-1249.

79) Watkins SL, Hogg RJ, Alexander SA, et al. Response to recombinant hepatitis B vaccine (Recombivax HB) in children wih chronic renal failure. J Am Soc Nephrol. 1994; 5: 344.

80) Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 1997; 48: 1-37.

81) Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensate liver disease. Am J Gastroenterol. 1999; 94: 1601-1604.

82) Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995; 90: 201-205.

83) Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998; 27: 881-886.

84) Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998; 338: 286-290.

85) Willner IR, Uhl MD, Howard SC, et al. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med. 1998; 128: 111-114.

86) Furth SL, Sullivan EK, Neu AM, et al. Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatric

Transplantation. 1997; 1: 37-42.

87) Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics. 1992;

90: 216-220.

88) Soave R. Prophylaxis strategies for solid-organ transplantation. Clin Infect Dis. 2001; 33(Suppl 1):

S26-31.

89) Avery RK. Infections and immunizations in organ transplant recipients: a preventive approach.

Cleve Clin J Med. 1994; 61: 386-392.

90) Kusne S, Krystofiak S. Infecion control issues after bone marrow and solid organ transplantation, in:

Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections. Philadelphia: Lippincott-Raven, 1998:

21-36.

91) Rubin RH. Cytomegalovirus infection in the liver transplant recipient: epidemiology, pathogenesis and clinical management. Liver Transplantation. 1997; 2: 439-452.

92) Flume PA, Egan TM, Paradowski LJ, et al. Infectious complications of lung transplantation: impact of cystic fibrosis. Am J Respir Crit Care Med. 1994; 149: 1601-1607.

93) Dennis C, Caine N, Sharples L, et al. Heart-lung transplantation for end-stage respiratory disease in

patients with cystic fibrosis at Papworth hospital. J Heart Lung Transplant. 1993; 12: 893-902.

94) Snell GL, de Hoyos A, Krajden M, et al. Pseudomonas cepacia in lung transplantation recipients with cystic fibrosis. Chest. 1993; 103: 466-471.

95) Ramirez JC, Patterson GA, Winton T, et al. Bilateral lung transplantation for cystic fibrosis. J Thorac Cardiovasc Surg. 1992; 103: 287-294.

96) Van der Waaij D. Colonization resistance of the digestive tract: clinical consequences and implications. J Antimicrob Chemoter. 1982; 10: 263-270.

97) Stoutenbeek C, Van Saens H, Mirande D, et al. A new technique of infection prevention in the intensive care unit by selective decontamination of the digestive tract. Acta Anaesthesiol Belg. 1983; 34:

209-221.

98) Raakov R, Steffer R, Lefebre B, et al. Selective bowel decontamination effectively prevents gram- negative bacterial infections after liver transplantation. Transplant Proc. 1990; 22: 1556-1557.

99) Arnow PM. Prevention of bacterial infection in the transplant recipient: the role of selective bowel decontamination. Infect Dis Clin North Am. 1995; 9: 849-862.

100) Weisner RH. The incidence of gram-negative bacterial and fungal infection in liver transplant patient treated with selective decontamination. Infection. 1990; 18: S19-21.

101) Weisner RH. Selective bowel decontamination for infection prophylaxis in liver transplantation patients. Transplant Proc. 1991; 23: 1927-1928.

102) Rosman C, Klompmaker IJ, Bonsel GJ, et al. The efficacy of selective bowel decontamination as infection prevention after liver transplantation. Transplantation Proc. 1990; 22: 1554-1555.

103) Rossaint R, Raakov R, Lewandowski K, et al. Strategy for prevention of infection after orthotopic liver transplantation. Transplant Proc. 1991; 23: 1965-1966.

104) Goresenk MJ, Carey WD, Washington JA, et al. Selective bowel decontamination with quinolones and nystatin reduces gram-negative and fungal infections in orthotopic liver transplant recipients. Cleve Clin J Med. 1993; 60: 139-144.

105) Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients:

impact and implications for management. Clin Infect Dis. 1998; 27: 1266-1277.

106) Higgins RSD, Kusne S, Reyes J, et al. Mycobacterium tuberculosis after liver transplantation:

management and guidelines for prevention. Clin Transplant. 1992; 6: 81-90.

107) Quniby WY, Al-Sibai MB, Taher S, et al. Mycobacterial infection after renal transplantation:

report of 14 cases and review of the literature. Q J Med. 1990; 77: 1039-1060.

108) Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Rev Infect Dis. 1983; 5: 216-226.

109) Naqvi SA, Hussain M, Askari H, et al. Is there a place for prophylaxis against tuberculosis following renal transplantation? Transplant Proc. 1992; 24: 1912.

110) Lloveras J, Peterson PK, Simmons RL, et al. Mycobacterial infections in renal transplant recipients:

seven cases and a review of literature. Arch Intern Med. 1982; 142: 888-892.

111) Aguado JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in

kidney, liver and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group,

GESITRA. Transplantation. 1997; 63: 1278-1286.

112) Salizzoni JL, Tiruviluamala P, Reichman LB. Liver transplantation: an unheralded probable risk for tuberculosis. Tuber Lung Dis. 1992; 73: 232-238.

113) John GT, Thomas PP, Thomas M, et al. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation. 1994; 57: 1683-1684.

114) Antony SJ, Ynares C, Dummer JS. Isoniazid hepatotoxicity in renal transplant recipients. Clin transplant. 1997; 11: 34-37.

115) Sakhuja V, Jha V, Verma PP, et al. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation. 1996; 61: 211-215.

116) Sterneck M, Ferrell L, Ascher N, et al. Mycobacterial infection after liver transplantation: a report of three cases and review of the literature. Clin Transplant. 1992; 6: 55-61.

117) Tolkoff-Rubin NE, Cosimi AB, Russell PS, et al. A controlled study of trimethoprim-

sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. Rev Infect Dis.

1982; 4: 614-618.

118) Fox BC, Sollinger HW, Belzer FO, et al. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorbition, trimethoprim-sulfamethoxazole effects on the microflora, and the cost-benefit of prophylaxis.

Am J Med. 1990; 89: 255-274.

119) Maki DG, Fox BC, Kuntz J, et al. A prospective, randomized, double-blind study of trimethoprim- sulfomethoxazole for prophylaxis of infection in renal transplantation: side effects of trimethoprim- sulfamethoxazole, interaction with cyclosporine. J Lab Clin Med. 1992; 119: 11-24.

120) Hibberd PL, Tolkoff-Rubin NE, Doran M, et al. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients: a double-blind, randomized controlled trial. Online J Curr Clin Trials. 1992; (Aug 11): doc.no.15.

121) Moyses-Neto M, Costa RS, Reis MA, et al. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients. Clin Transplant. 1997; 11: 446-452.

122) Fishman JA. Pneumocystis carinii and parasitic infections in transplantation [review]. Infect Dis Clin North Am. 1995; 9: 1005-1044.

123) Wreghitt TG, Gray JJ, Pavel P, et al. Efficacy of pyrimethamine for the prevention of donor-acquired Toxoplasma gondii infection in heart and heart-lung transplant patients. Transplant Int. 1992; 5: 197- 200.

124) Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human

immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004; 17: 770-782.

125) Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis. 2000; 2:

112-117.

126) Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation. 2006; 81: 1645-1652.

127) Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000; 356 (9230): 645.

128) Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset cytomegalovirus disease in liver

transplant recipients despite antiviral prophylaxis. Transplantation. 2004; 78 (9): 1390.

129) Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late- onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis wth oral ganciclovir. J Infect Dis. 2001; 184 (11): 1461.

130) Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004; 4 (4):

611.

131) Duncan SR, Grgurich WF, Iacono AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 1994; 150 (1): 146.

132) Shibolet O, Ilan Y, Kalish Y, et al. Late cytomegalovirus disease following liver transplantation.

Transpl Int. 2003; 16 (12): 861.

133) Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant. 2003; 3 (6): 731.

134) Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant. 2006; 6: 386-391.

135) Dummer JS, Lazariashvilli N, Barnes J, et al. A survey of antifungal management in lung transplantation. J Heart Lung Transplant. 2004; 23: 1376-1381.

136) Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis. 2003; 37:

221-229.

137) Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am. 2003; 17: 113-134.

138) George MJ, Snydman DR, Werner Bg, et al. The indipendent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med. 1997; 103: 106- 113.

139) Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation. 1996; 62: 926-934.

140) Karchmer AW, Samore MH, Hadley S, et al. Fungal infections complicating orthotopic liver transplantation. Trans Am Clin Climatol Assoc. 1994; 106: 38-48.

141) Fortun JP, Martin-Davila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 2002; 8: 1065-1070.

142) Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis. 2003; 36: 46-52.

143) Singh N. Antifungal prophylaxis in organ transplant recipients: seeking clarity admist controversy.

Clin Infect Dis. 2000; 31: 545-553.

144) Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis. 2004; 39 (Suppl 4): S200-206.

145) Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients.

Antimicrob Agents Chemoter. 1993; 37: 619-624.

146) Wagener MM, Yu VL, Bacteremia in transplant recipients: a prospective study of demographics,

etiologic agents, risk factors and outcomes. Am J Infect Control. 1992; 20: 239-247.

147) Dunn DL. Problems related to immunosuppression: infection and malignancy occurring after solid organ transplantation. Crit Care Clin. 1990; 6: 955-977.

148) Prat V, Horciekova M, Matousovic M, et al. Urinary tract infections in renal transplant patients.

Infection. 1985; 13: 207-210.

149) Lapchick MS, Castelo-Filho A, Pestana JO, et al. Risk factors for nosocomial urinary tract and postoperative wound infections in renal transplant patients: a matched-pair case-control study. J Urol.

1992; 147: 994-998.

150) DoudzdjianV, Abecassis MM, Cooper JL, et al. Incidence, management and significance of surgical complications after pancreatic transplantation. Surg Gynecol Obstet. 1993; 177: 451-456.

151) Ho M, Dummer JS, Peterson PK, et al. Le infezioni nei riceventi trapianto di organi solidi. In:

Mandell GL, Douglas G Jr, Bennett JE, Principi e pratica delle malattie infettive, Padova, Piccin Nuova Libraria.

152) Griffin PJA, Salaman JR. Urinary tract infections after renal transplantation: Do they matter. Br Med J. 1979; 1: 710-711.

153) Gillum DM, Kelleher SP. Acute pielonephritis as a cause of late transplant disfunction. Am J Med.

1985; 78: 156-158.

154) Everett JE, Wahoff DC, Statz C, et al. Characterization and impact of wound infection after pancreas transplantation. Arch Surg. 1994; 129: 1310-1317.

155) Steffenson DO, Dummer JS, Granick MS, et al. Mycoplasma hominis median sternotomy infections.

Ann Intern Med. 1987; 106: 204-208.

156) Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation, an analysis of 101 consecutive cases. Medicine. 1988; 67: 132-143.

157) Church JM, Fazio VW, Braun WE, et al. Perforation of the colon in renal homograft recipients. Ann Surg. 1986; 203: 69-76.

158) Pollak R, Hau T, Mozes MF, et al. The spectrum of peritonitis in renal transplant recipients. Am Surg. 1985; 51: 617-620.

159) Alexander P, Schuman E, Vetto RM. Perforation of the colon in the immunocompromised patient.

Am J Surg. 1986; 151: 557-561.

160) Pirenne J, Lledo-Garcia E, Benedetti E, et al. Colon perforation after renal transplantation: a single-institution review. Clin Transplant. 1997; 11: 94-97.

161) Hau T, Van Hook EJ, Simmons RL, et al. Prognostic factors of peritoneal infections in transplant patients. Surgery. 1978; 84: 403-408.

162) Mermel LA, Maki DG. Bacterial pneumonia in solid organ transplantation. Semin Respir Infect.

1990; 5: 10-29.

163) Dunn DL, Najarian JS. Infectious complications in transplant surgery. In: Shires GT, Davis J, eds.

Principles and management of surgical infection. Philadelphia. JB Lippincott. 1990: 425-464.

164) Deusch E, End A, Grimm M, et al. Early bacterial infections in lung transplant recipients. Chest.

1993; 104: 1412-1416.

165) Keating MR, Wilhelm MP, Walker RC. Strategies for prevention of infection after cardiac

166) Horvath J, Dummer S, Loyd J, et al. Infection in the transplanted and native lung after single lung transplantation. Chest. 1993; 104: 681-685.

167) Mauer JR, Tullis DE, Grossman RF, et al. Infectious complications following isolated lung transplantation. Chest. 1992; 101: 1056-1059.

168) Ammple NM, Wing EJ. Legionella infection in transplant patients. Semin Respir Infect. 1990; 5:

30-37.

169) Meyerowitz RL, Pasculle AW, Dowling JN, et al. Opportunistic lung infection due to “Pittsburgh Pneumonia Agent”. N Engl J Med. 1979; 301: 953-958.

170) Brayman KL, Stephanian E, Matas J, et al. Analysis of infectious complications occurring after solid organ transplantation. Arch Surg. 1992; 127: 38-48.

171) Kramer MR, Marshall SE, Starnes VA, et al. Infectious complications in heart-lung transplantation analysis of 200 episodes. Arch Intern Med. 1993; 153: 2010-2016.

172) Sinnott JT, Emmanuel PJ. Mycobacterial infections in the transplant patient. Semin Respir Infect.

1990; 5: 65-73.

173) Hall CM, Willcox PA, Swanepoel CR, et al. Mycobacterial infection in renal transplant recipients.

Chest. 1994; 106: 435-439.

174) Higgins RSD, Kusne S, Reyes J, et al. Mycobacterium tuberculosis after liver transplantation:

management and guidelines for prevention. Clin Transplant. 1992; 6: 81-90.

175) Ridgeway AL, Warner GS, Phillips P, et al. Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor. Am J Respir Crit Care Med. 1996; 153: 1166- 1168.

176) Peters TG, Reiter CG, Boswell RL. Transmission of tuberculosis by kidney transplantation.

Transplantation. 1984; 38: 514-516.

177) Delaney V, Sumrani KN, Hong JH, et al. Mycobacterial infections in renal allograft recipients.

Transplant Proc. 1993; 25: 2288-2289.

178) Cavusoglu C, Cicek-Saydam C, Karasu Z, et al. Mycobacterium tuberculosis infection and laboratory diagnosis in solid-organ transplant recipients. Clin Transplant. 2002; 16: 257-261.

179) Nicholson V, Johnson PC. Infectious complications in solid organ transplant recipients. Surg Clin North Am. 1994; 74: 1223-1245.

180) Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis. 1993; 16: 677-688.

181) Zeluff BJ. Fungal pneumonia in transplant recipients. Semin Respir Infect. 1990; 5: 80-89.

182) Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine. 1999; 78: 123-138.

183) Dockrell DH, Mendez JC, Jones M, et al. Human herpesvirus 6 seronegativity before

transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation.

1999; 67: 399-403.

184) Rogers J, Singh N, Carrigan DR, et al. Clinical relevance of human herpesvirus-6 infection in liver

transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and impact on

outcome. Transplantation. 2000; 69: 2566-2573.

185) Keating MR, Guerrero MA, Daly RC, et al. Transmission of invasive aspergillosis from a

subclinically infected donor to three different organ-transplant recipients. Chest. 1996; 109: 1119-1124.

186) Kusne S, Torre-Cisneros J, Manez R, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis. 1992; 166: 1379- 1383.

187) Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients: report of 9 cases and review of the literature. Medicine (Baltimore). 1996; 75: 142-156.

188) Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997; 112: 1160-1164.

189) Nunley DR, Ohori Np, Grgurich WF, et al. Pulmonary aspergillosis in in cystic fibrosis lung transplant recipients. Chest. 1998; 114: 1321-1329.

190) Paradowski LJ. Saprophytic fungal infections and lung transplantation-revisited. J Heart Lung Transplant. 1997; 16: 524-531.

191) Torre-Cisnero J, Lopez OL, Kusne S, et al. CNS aspergillosis in organ transplantation: a clinicopathologic study. J Neurol Neurosurg Psychiatry. 1993; 56: 188-193.

192) Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in 1990s.

Transplantation. 1997; 64: 716-720.

193) Bonham CA, Dominguez EA, Fukui MB, et al. Central nervous system lesions in liver transplant recipients: a prospective assessment of indications for biopsy and implications for management.

Transplantation. 1998; 66: 1596-1604.

194) Verweij PE, Poulain D, Obayashi T, et al. Current trends in the detection of antigenemia,

metabolites, and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections. Med Mycol. 1998; 36: 146-155.

195) Singh N, Linden PK, Munoz P, et al. Emerging trends in invasive mold infections in organ transplant recipients [abstract]. Presented at the 40

Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 2000.

196) Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis.

2001; 32: 1237-1240.

197) Singh N, Gayowski T, Yu VL. Invasive gastrointestinal zygomycosis in a liver transplant recipient:

case report and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis. 1995; 20:

617-620.

198) Jabbour N, Reyes J, Kusne S, et al. Cryptococcal meningitis after liver transplantation.

Transplantation. 1996; 61: 146-167.

199) John GT, Mathew M, Snehaltha E, et al. Cryptococcosis in renal allograft recipients.

Transplantation. 1994; 58: 855-856.

200) Husain S, Wagener MM, Singh N, et al. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 2001; 7: 1-7.

201) Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis. 2001; 33: 1397-1405.

202) Sawyer MD, Mayoral JL, Gillingham KJ, et al. Treatment of recurrent cytomegalovirus disease in

patients receiving solid-organ transplants. Arch Surg. 1993; 128: 165-170.

203) Dunn DL, Mayoral JL, Gillingham KJ, et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation. 1991; 51: 98-106.

204) Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation – challenging the status quo. Clin Transplant. 2007; 21: 149-158.

205) Rowshani AT, Frederike JB, van Leeuwen EM, et al. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation. 2005; 79: 381-386.

206) Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995; 20: 1346-1353.

207) von Willebrand E, Pettersson E, Ahonen J, et al. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation. 1986; 42: 364.

208) Ustinov JA, Loginov RJ, Bruggeman CA, et al. Cytomegalovirus induces class II expression in rat heart endothelial cells. J Heart Lung Transplant. 1993; 12: 644.

209) Kloover JS, Soots AP, Krogerus LA, et al. Rat cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellulare adhesion molecule-1, vascular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft.

Transplantation. 2000; 69: 2641.

210) Koskinen PK. The association of the induction of vascular cell adhesion molecule-1 with cytomegalovirus antigenemia in human heart allografts. Transplantation. 1993; 56: 1103.

211) Magnan A, Mege JL, Reynaud M, et al. Monitoring of alveolar macrophage production of tumor necrosis factor-alpha and interleukin-6 in lung transplant recipients. Marseille and Montreal Lung Transplantation Group. Am J Respir Crit Care Med. 1994; 150: 684.

212) Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989; 261: 3561-3566.

213) O'Grady JG, Alexander GJ, Sutherland S, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdipendent cofactors in pathogenesis of vanishing bile duct syndrome after liver

transplantation. Lancet. 1988; 2: 302-305.

214) Richardson WP, Colvin RB, Cheeseman SH, et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med. 1981; 305: 57-63.

215) Levitsky J, Freifeld AG, Puumala S, et al. Cytomegalovirus viremia in solid organ transplantation:

does the initial viral load correlate with risk factors and outcomes? Clin Transpl. 2008; 22: 222-228.

216) Meyer-Koenig U, Weidmann M, Kirste G, et al. Cytomegalovirus infection in organ-transplant recipients: diagnostic value of pp65 antigen test, qualitative polymerase chain reaction (PCR) and quantitative Taqman PCR. Transplantation. 2004; 77: 1692-1698.

217) Preiksaitis JK. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis. 2004; 39: 1016-1023.

218) Langnas AN, Castaldo P, Markin RS, et al. The spectrum of Epstein-Barr virus infection with hepatitis following liver transplantation. Transplant Proc. 1991; 23: 1513-1514.

219) Preiksaitis JK, Keay S. Diagnosis and management of posttransplant lymphoproliferative disorders

in solid organ transplant recipients. Clin Infect Dis. 2001; 33 (Suppl 1): S38-46.

220) Dharnidharka VR, Sullivan EK, Starblein DM, et al. Risk factors for posttransplant

lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation. 2001; 71: 1065-1068.

221) Paya CV, Fung JJ, Nalesnik MA, et al. Epstein Barr virus-induced posttransplant

lymphoproliferative disorders: ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation. 1999; 68: 1517-1525.

222) Harris NL, Ferry JA, Swerdlow SH, et al. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol. 1997; 14: 8-14.

223) Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation: interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation. 1996; 62: 370-375.

224) Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol. 1988;

133: 173-192.

225) Rowe DT, Qu L, Reyes J, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol. 1997; 35: 1612-1615.

226) Green M, Webber SA. EBV viral load monitoring: unanswered questions. Am J Transplant. 2002; 2:

894-895.

227) Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004; 350: 1328-1337.

228) Kuppers R. B-cells under influence: transformation of B-cells by Epstein-Barr virus. Nat Rev Immunol. 2003; 10: 801-812.

229) Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder.

Transplant Infect Dis. 2001; 3: 70-78.

230) Stevens SJC, Verschuuren EAM, Verkuijlen SA, et al. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma. 2002; 43: 831-840.

231) Axelrod DA, Holmes R, Thomas SE, et al. Limitations of EBV-PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder. Pediatr Transplant. 2003; 7: 223-227.

232) Smith JM, Corey L, Healey PJ, et al. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation. 2007; 83: 1423-1428.

233) Anderson DJ, Jordan MC. Viral pneumonia in recipients of solid organ transplants. Semin Respir Infect. 1990; 5: 38-49.

234) Carrier M, Pelletier GB, Cartier R, et al. Prevention of herpes simplex virus infection by oral acyclovir after cardiac transplantation. Can J Surg. 1992; 35: 513-516.

235) Dunn DL, Matas AJ, Fryd DS, et al. Association of concurrent herpes simplex virus and cytomegalovirus with detrimental effects after renal transplantation. Arch Surg. 1984; 119: 812-817.

236) Straus SE, Ostrove JM, Inchaupse G, et al. Varicella-zoster infections biology, natural history,

treatment, and prevention. Ann Intern Med. 1988; 108: 221-237.

237) Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics.

1992; 90: 216-220.

238) Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α2b and ribavirin: an open-label series.

Transplantation. 2004; 77: 190-194.

239) Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998; 28 (3): 823.

240) Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996; 334 (13): 815.

241) Feray C, Gigou M, Samuel D, et al. The course of hepatitis C infection after liver transplantation.

Hepatology. 1994; 20 (5): 1137.

242) Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000; 32 (4): 852.

243) Sanchez-Fueyo A, Restrepo JC, Quinto L, et al. Impact of the reccurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation. 2002; 73 (1):

56.

244) Gane E. Treatment of recurrent hepatitis C. Liver Transpl. 2002; 8 (Suppl 1): S28.

245) Rosen HR, Martin P. Liver transplantation in patients with chronic hepatitis B and C. In:

Transplantation of the Liver. Philadelphia, Lippincott Williams & Wilkins, 2001.

246) Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993; 329: 1842-1847.

247) Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998; 28: 823-830.

248) Razonable RR, Brown RA, Humar A, et al. A longitudinal molecular surveillance study on human polyomavirus viremia in heart, kidney, liver and pancreas transplant patients. J Infect Dis. 2005; 192:

1349-1354.

249) Mylonakis E, Goes N, Rubin RH, et al. BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation. 2001; 72: 1587-1592.

250) Heilbronn R, Albrecht I, Stephan S, et al. Human cytomegalovirus induces JC virus DNA replication in human fibroblasts. Proc Natl Acad Sci USA. 1993; 90: 11406-11410.

251) Winklhofer KF, Albrecht I, Wegner M, et al. Human cytomegalovirus immediate-early gene 2 expression leads to JCVreplication in nonpermissive cells via transcriptional activation of JCV T antigen.

Virology. 2000; 275: 323-334.

252) Goldstein SC, Tralka TS, Rabson AS. Mixed infection with human cytomegalovirus and human polyomavirus (BKV). J Med Virol. 1984; 13: 33-40.

253) Hooper DC, Pruitt AA, Rubin RH. Central nervous system infections in the cronically immunosuppressed. Medicine (Baltimore). 1982; 61: 166-188.

254) Neuberger J. Immunosoppressive drugs. In: Transplantation of the Liver, Philadelphia, Lippincott

Williams & Wilkins, 2001.

255) Menichetti F, et al. Fever, mental impairment, acute anemia, and renal failure in patient undergoing orthotopic liver transplantation: posttransplantation malaria. Liver Transplantation. 2006; 12: 674-676.

256) United Network for Organ Sharing. Report of center specific graft and patient survival rates. In:

2002 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1992-2001.

257) Del Bono L, Filipponi F, Marchetti G, Ferranti S, Menichetti F, Mosca F. A 59-years-old liver- transplanted woman with fever, dyspnea and pulmonary infiltrates. Clin Microbiol Infect. 2003; 9 (10):

1057-1061.

258) De Simone P, Carrai P, Morelli L, Coletti L, Petruccelli S, Filipponi F, Doria R, Menichetti F, Vannozzi R. Posttransplant hepatocellular carcinoma metastasis at a skull trauma site. Transplantation.

2005; 80 (9): 1358-1359.

259) Biancofiore G, Bisa M, Bindi LM, Urbani L, Tascini C, Menichetti F, Filippini F. Liver transplantation due to Herpes Simplex virus-related sepsis causing massive hepatic necrosis after thoracoscopic thymectomy. Minerva Anestesiol. 2007; 73 (5): 319-322.

260) Biancofiore G, Tascini C, Bisa M, Gemignani G, Bindi ML, Leonildi A, Giannotti G, Menichetti F.

Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report. Minerva Anestesiol. 2007; 73 (3): 181-185.

261) De Simone P, Petruccelli S, Precisi A, Carrai P, Doria R, Menichetti F, Filipponi F. Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient – not all proliferation signal inhibitors are the same: a case report. Transplant Proc. 2007; 39 (10): 3500-3501.

262) Urbani L, Mazzoni A, Colombatto P, Biancofiore G, Bindi L, Tascini C, Menichetti F, Brunetto M, Scatena F, Filipponi F. Potential applications of extracorporeal photopheresis in liver transplantation.

Transplant Proc. 2008; 40 (4): 1175-1178.

263) Urbani L, Mazzoni A, Bianco I, Grazzini T, De Simone P, Catalano G, Montin U, Petruccelli S, Morelli L, Campani D, Pollina L, Biancofiore G, Bindi L, Tascini C, Menichetti F, Scatena F, Filipponi F. The role of immunomodulation in AB0-incompatibile adult liver transplant recipients. J Clin Apher.

2008; 23 (2): 55-62.